NANOVIRICIDES, INC.
NNVC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NNVC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NNVC
Nanoviricides, Inc. is a clinical-stage biotechnology company developing novel nanomicelle-based antiviral drugs, with its lead candidate NV-387 being evaluated in a Phase 1a/1b trial for COVID-19 and other viral indications. The company has no approved products or revenues and relies on partnerships and capital markets for funding.
Key risk: No revenue or profitability
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 5 pipeline candidates for NANOVIRICIDES, INC..
Nanoviricides, Inc. is a clinical-stage biotechnology company developing novel nanomicelle-based antiviral drugs, with its lead candidate NV-387 being evaluated in a Phase 1a/1b trial for COVID-19 and other viral indications. The company has no approved products or revenues and relies on partnerships and capital markets for funding.
- Lead drug candidate NV-387 (NV-CoV-2) is in Phase 1a/1b clinical trial for COVID-19 and long COVID [sec_mda · as of 2023-05-15].
- No approved drugs, customers, or revenues to date; may never achieve profitable operations [sec_mda · as of 2025-02-14].
- Cash and equivalents of $3.2M as of 2026-03-31 [sec]; net loss of $2.0M for the period [sec].
- Pipeline includes preclinical candidates for RSV, MPox, herpes viruses, HIV, influenza, and other viruses [sec_mda · as of 2023-05-15].
- Company seeks to out-license drug candidates and pursue non-dilutive grant funding [sec_mda · as of 2025-02-14].
What works
- Nanoviricides has a proprietary nanomicelle platform that can be rapidly adapted to new viruses, potentially shortening development timelines [sec_mda · as of 2024-02-14].
- The company has established internal cGMP manufacturing capabilities for oral drug products and plans for injectable formulations via third-party CMOs [sec_mda · as of 2023-02-14].
- Management believes several assets are worthy of partnering, which could provide early revenue through license fees and milestones [sec_mda · as of 2025-02-14].
What to weigh
- The company has no approved products, no revenues, and a history of operating losses; it may never achieve profitability [sec_mda · as of 2025-02-14].
- Cash position of $3.2M as of 2026-03-31 is limited, and the company's ability to continue as a going concern depends on securing additional financing [sec_mda · as of 2024-11-14].
- Clinical timelines are subject to delays due to factors outside the company's control [sec_mda · as of 2024-02-14].
- The stock is currently undervalued according to management, but liquidity and market access remain uncertain [sec_mda · as of 2025-02-14].
From the filings
Quoted directly from source documents.
No approved drugs or revenues
“We do not have any approved drugs on the market as of now. We have no customers, products or revenues to date, and may never achieve revenues or profitable operations.”
SEC MD&A · February 14, 2025
Lead candidate in Phase 1a/1b trial
“We are a clinical stage company with our first drug in Phase 1a/1b clinical trial”
SEC MD&A · February 14, 2024
Going concern dependency on financing
“to continue as a going concern is dependent upon controlling its overall expenses and identifying and securing additional financing.”
SEC MD&A · November 14, 2024
Risks & what to watch (4)›
Key risks
- No revenue or profitability — No approved products or revenues; may never achieve profitable operations [sec_mda · as of 2025-02-14].
- Limited cash runway — Cash of $3.2M as of 2026-03-31; going concern depends on additional financing [sec_mda · as of 2024-11-14].
- Clinical trial delays — Timelines depend on assumptions outside company control and are subject to delays [sec_mda · as of 2024-02-14].
- Stock liquidity and valuation — Management believes stock is undervalued; liquidity improvement depends on milestones [sec_mda · as of 2025-02-14].
What to watch
- Release of Phase 1a/1b clinical trial final report for NV-CoV-2 [sec_mda · as of 2024-11-14].
- Pre-IND application for NV-387 in RSV infections [sec_mda · as of 2024-11-14].
- Clinical trial applications (including US FDA IND) for NV-387 in RSV and/or MPox [sec_mda · as of 2024-11-14].
- Ability to secure additional financing through ATM agreement or partnerships [sec_mda · as of 2025-02-14].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run NANOVIRICIDES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NANOVIRICIDES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
5.1 months
D/E 0.12 · 0% dilution
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$1.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,022,954 | $933K |
| geode capital management, llc | 225,381 | $206K |
| blackrock, inc. | 158,752 | $145K |
| renaissance technologies llc | 134,900 | $123K |
| susquehanna international group, llp | 99,031 | $90K |
| vanguard fiduciary trust co | 90,060 | $82K |
| state street corp | 54,206 | $49K |
| bridgeway capital management, llc | 36,039 | $33K |
| citadel advisors llc | 35,900 | $33K |
| xtx topco ltd | 35,432 | $32K |
Showing top 10 of 46 institutional holders of NANOVIRICIDES, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 3.4%
- Days to cover
- 3.0
- Shares short
- 713,649
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NNVC short interestGovernance
Frequently asked questions
What is the AI investment thesis for NANOVIRICIDES, INC.?
Nanoviricides, Inc. is a clinical-stage biotechnology company developing novel nanomicelle-based antiviral drugs, with its lead candidate NV-387 being evaluated in a Phase 1a/1b trial for COVID-19 and other viral indications. The company has no approved products or revenues and relies on partnerships and capital markets for funding.
What is NANOVIRICIDES, INC.'s lead drug candidate?
NANOVIRICIDES, INC.'s most advanced tracked candidate is nv-387 (Phase 2) for COVID infection, RSV infection, Influenza, Smallpox, MPox.
Who is the CEO of NANOVIRICIDES, INC.?
Dr. Anil R. Diwan Ph.D. is the chief executive officer of NANOVIRICIDES, INC. (NNVC).
Where is NANOVIRICIDES, INC. headquartered?
NANOVIRICIDES, INC. (NNVC) is headquartered in Shelton, CT, United States.
What therapeutic areas does NANOVIRICIDES, INC. focus on?
NANOVIRICIDES, INC. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.